I. MODIFIED AGREEMENTS |
|||
Company* | Company* | Change from original agreement | Terms/Details (Date) |
| | |||
Argonaut | Symyx | Expanded agreement to give Argonaut exclusive and nonexclusive worldwide rights to make and sell integrated parallel pressure reactor systems under a broader collection of Symyx patents than was available under the prior deal | The agreement includes a provision allowing Argonaut to provide a buyer's license to use and prepare materials exclusively for screening in the licensed reactor system, under the licensed Symyx patents, without reach-through royalties (9/17) |
AVAX | Medigene AG | Extended production deal for processing clinical samples for Medigene's therapeutic vaccine to treat malignant melanoma | The contract extends and expands the previous manufacturing agreement by about one year (8/19) |
Cambridge | Xerion | Expanded business relation- ship to evaluate the therapeutic potential of a cell-surface protein known to play a role in human allergic reactions | CAT will provide specific human antibodies and Xerion will use its Xcalibur target validation technology to investigate new mechanisms of intervention in allergic disease; the parties will jointly own resulting intellectual property (8/13) |
Gilead Sciences | Primagen | Extended service testing agreement to measure mitochondrial DNA using Primagen's Retina Mitox test in samples of a multiyear, multicenter Phase III study of Viread | Primagen will continue the measurement in blood cell samples of individuals in a study of Viread in treatment-naive HIV-infected patients (9/23) |
Isis Pharma- | Hybridon Inc. | Modified agreement in which the companies canceled remaining financial obligations related to their collaboration and license agreement that dates to May 2001 | Hybridon owed Isis an additional 4M shares of Hybridon common stock, and Isis owed Hybridon $4.5M in cash or stock; both companies said the steps are aimed at avoiding further shareholder dilution (9/15) |
II. TERMINATED AGREEMENTS |
|||
Company* | Company* | Change from original agreement | Terms/Details (Date) |
| | |||
Amgen Inc. | Praecis Pharmaceuticals | Concluded agreement in which Praecis will pay Amgen $13M in a final settlement of all amounts payable under their collaboration agreement that was terminated by Amgen Dec. 17 | Amgen backed out of the $100M collaboration last year; it was focused on the prostate cancer drug Plenaxis (8/21) |
Cubist | Gilead Sciences | Terminated licensing agreement for the commercialization of Cidecin in Europe | The companies could not agree on whether to pursue European approval for Cidecin in the single indication of skin and soft-tissue infections or for a broader label (9/10) |
ReNeuron | Vistagen | Companies terminated their agreement for Vistagen to use ReNeuron's stem cells in drug discovery | The agreement was formed in July 2001 (9/18**) |
| | |||
Notes: | |||
# The information in the chart does not cover agricultural agreements. | |||
* Private companies are indicated with an asterisk. | |||
** Denotes the date the item ran in BioWorld International | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
LSE = London Stock Exchange | |||
